Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.81
Percentage change 1.91	%

Peers: INCY EXEL SAGE TXMD GNFT BLUE CARA DNLI BYSI MGNX

| Held by: VTI IWM VB XBI VXF VBK IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	1.86%	Shs Outstand	63.53M	Perf Week	1.01%
Market Cap	6.14B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-15.07%	Shs Float	62.34M	Perf Month	14.48%
Income	-128.05M	PEG	-	EPS next Q	-0.70	Inst Own	103.58%	Short Float	6.63%	Perf Quarter	2.19%
Sales	434.41M	P/S	14.13	EPS this Y	88.32%	Inst Trans	1.51%	Short Ratio	6.69	Perf Half Y	-5.64%
Book/sh	4.93	P/B	19.58	EPS next Y	9.00%	ROA	-11.11%	Short Interest	4.13M	Perf Year	45.73%
Cash/sh	11.56	P/C	8.36	EPS next 5Y	-	ROE	-49.66%	52W Range	64.79 - 121.90	Perf YTD	4.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.19%	ROI	-13.80%	52W High	-20.74%	Beta	0.58
Dividend TTM	-	Quick Ratio	3.27	Sales past 5Y	220.20%	Gross Margin	93.83%	52W Low	49.12%	ATR (14)	4.07
Dividend Ex-Date	-	Current Ratio	3.32	EPS Y/Y TTM	77.64%	Oper. Margin	-63.52%	RSI (14)	57.33	Volatility	5.47% 4.39%
Employees	655	Debt/Eq	2.34	Sales Y/Y TTM	100.93%	Profit Margin	-29.48%	Recom	1.75	Target Price	125.58
Option/Short	Yes / Yes	LT Debt/Eq	1.96	EPS Q/Q	59.70%	Payout	-	Rel Volume	1.26	Prev Close	94.81
Sales Surprise	0.50%	EPS Surprise	7.40%	Sales Q/Q	126.61%	Earnings	Oct 30 BMO	Avg Volume	617.48K	Price	96.62
SMA20	3.82%	SMA50	7.05%	SMA200	0.64%	Trades		Volume	778,919	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Initiated	JP Morgan	Overweight	$126
Oct-24-24	Initiated	UBS	Neutral	$88
May-14-24	Initiated	Stephens	Overweight	$140
May-06-24	Upgrade	Leerink Partners	Underperform → Market Perform	$50 → $97
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform	$85
Aug-21-23	Reiterated	Needham	Buy	$65 → $66
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$55 → $82
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform	$48 → $43
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$41
Dec-14-22	Initiated	Needham	Buy	$60
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy	$90
Jul-08-22	Initiated	Oppenheimer	Outperform	$80
Jun-27-22	Initiated	Wells Fargo	Underweight	$40
Jun-10-22	Downgrade	Citigroup	Neutral → Sell	$68 → $41
Jun-01-22	Upgrade	Jefferies	Hold → Buy	$88 → $78
Mar-01-22	Initiated	Citigroup	Neutral	$71
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$82
Jan-25-22	Upgrade	Stifel	Hold → Buy	$120 → $95
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$111

Show Previous Ratings

Nov-14-24 03:18PM	Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst (Benzinga)
Oct-31-24 03:05AM	Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... (GuruFocus.com)
12:04AM	Q3 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-24 08:10AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.00%
07:10AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Oct-23-24 10:01AM	Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-21-24 12:00PM	Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-16-24 08:00AM	Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 (PR Newswire)
Oct-15-24 09:55AM	Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know (Zacks)
Sep-10-24 08:00AM	Blueprint Medicines to Present at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 07:00PM	Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Aug-09-24 09:55AM	Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Aug-02-24 10:44AM	Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat (Zacks)
Aug-01-24 08:05AM	Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.40%
07:05AM	Loading…
07:05AM	Blueprint Medicines: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Jul-25-24 10:02AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-18-24 08:00AM	Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 (PR Newswire)
Jun-25-24 12:39PM	How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park' (Investor's Business Daily)
Jun-07-24 09:15PM	Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Jun-06-24 07:01PM	Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares (GuruFocus.com)
May-30-24 06:01PM	Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib) (PR Newswire) +5.76%
May-23-24 05:05PM	Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 07:50AM	Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target (MT Newswires)
May-06-24 05:32PM	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing (MT Newswires)
04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:45AM	Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating (MT Newswires)
07:05AM	Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 (MT Newswires)
May-03-24 10:03AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:51AM	Loading…
09:51AM	Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises (Zacks)
03:05AM	Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ... (GuruFocus.com)
May-02-24 09:24PM	Q1 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +12.80%
11:56AM	BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:56AM	Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating (MT Newswires)
10:16AM	Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises (MT Newswires)
08:36AM	Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ... (GuruFocus.com)
08:10AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:11AM	Blueprint Medicines: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Apr-25-24 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-18-24 08:00AM	Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 (PR Newswire)
Apr-11-24 08:00AM	Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics (PR Newswire)
Apr-04-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 07:00PM	Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares (GuruFocus.com)
Mar-06-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:53AM	Q4 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-23-24 08:00AM	Blueprint Medicines Highlights AYVAKIT (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting (PR Newswire)
Feb-16-24 03:30PM	Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings (Zacks)
09:37AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:47AM	Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines (Zacks)
Feb-15-24 10:50PM	Q4 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +14.02%
10:55AM	Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat (Investor's Business Daily)
08:25AM	Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
07:26AM	Blueprint Medicines: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. (Investor's Business Daily)
07:00AM	Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-12-24 09:16AM	Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Feb-08-24 10:00AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-01-24 08:00AM	Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 (PR Newswire)
Jan-16-24 12:00PM	What Makes Blueprint Medicines (BPMC) a New Buy Stock (Zacks)
11:51AM	Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now (Zacks)
Jan-09-24 01:51PM	Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets. (Barrons.com)
Jan-08-24 08:00AM	Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-18-23 08:00AM	Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:05AM	Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Dec-12-23 08:05AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis (PR Newswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-09-23 12:30PM	Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting (PR Newswire)
Dec-04-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-28-23 08:00AM	Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Blueprint Medicines Corp (GuruFocus.com) +9.97%
Nov-13-23 04:29PM	Oppenheimer Expects the S&P 500s Advance to Continue Into 2024 Heres Why These 2 Stocks Might Be Worth Buying (TipRanks)
Nov-10-23 08:00AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis (PR Newswire)
Nov-04-23 03:02AM	Director Jeffrey Albers Sells 10,000 Shares of Blueprint Medicines Corp (GuruFocus.com)
Nov-03-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-31-23 09:55AM	How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16% (Zacks) +8.32%
09:40AM	Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year? (Zacks)
03:48AM	5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-28-23 01:49PM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
07:27AM	Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat (Zacks)
Oct-26-23 11:42PM	Q3 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +25.61%
05:47PM	Why Blueprint Medicines Stock Soared Today (Motley Fool)
09:30AM	Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics (Zacks)
08:52AM	Blueprint Medicines Corp (BPMC) Reports Q3 2023 Earnings (GuruFocus.com)
08:15AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:09AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Third Quarter 2023 Results (PR Newswire)
Oct-25-23 10:15AM	Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC (Zacks)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)
Oct-20-23 10:00AM	AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-19-23 10:01AM	Earnings Preview: Blueprint Medicines (BPMC) Q3 Earnings Expected to Decline (Zacks) -5.27%
Oct-12-23 08:00AM	Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 (PR Newswire)

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONNEL COATS	Director	Nov 21 '24	Proposed Sale	94.81	9,824	931,413		Nov 21 04:23 PM
LONNEL COATS	Director	Nov 20 '24	Proposed Sale	94.60	10,000	946,000		Nov 20 04:30 PM
Albers Jeffrey W.	Director	Nov 07 '24	Option Exercise	36.05	5,000	180,250	162,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Sale	102.00	5,000	510,000	157,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Proposed Sale	102.00	5,000	510,000		Nov 07 05:24 PM
Namouni Fouad	PRESIDENT, R & D	Oct 03 '24	Sale	89.32	3,633	324,500	69,070	Oct 04 05:09 PM
Albers Jeffrey W.	Director	Sep 09 '24	Option Exercise	36.05	10,000	360,500	177,259	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Sale	85.57	19,702	1,685,891	157,557	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Proposed Sale	85.57	19,702	1,685,911		Sep 09 09:22 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Aug 15 '24	Sale	95.23	4,409	419,869	67,208	Aug 19 04:00 PM
MICHAEL LANDSITTEL	Officer	Aug 15 '24	Proposed Sale	95.23	4,409	419,891		Aug 15 04:27 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Option Exercise	67.50	41,913	2,828,921	76,642	Aug 07 05:06 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	93.19	41,913	3,905,872	34,729	Aug 07 05:06 PM
Lee Philina	Officer	Aug 05 '24	Proposed Sale	93.00	46,436	4,318,548		Aug 05 04:50 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Option Exercise	54.13	8,817	477,264	52,580	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Option Exercise	54.13	3,850	208,400	47,613	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Sale	111.29	8,817	981,244	43,763	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Sale	111.20	3,850	428,120	43,763	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 28 '24	Option Exercise	54.13	333	18,025	44,096	Jul 02 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 28 '24	Sale	111.15	333	37,013	43,763	Jul 02 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 21 '24	Option Exercise	34.48	60,482	2,085,501	117,797	Jun 25 04:00 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 21 '24	Sale	104.19	74,034	7,713,537	43,763	Jun 25 04:00 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 05 '24	Sale	105.13	4,000	420,520	41,895	Jun 07 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	104.91	2,424	254,302	29,514	Jun 06 04:00 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 03 '24	Sale	106.43	2,436	259,263	45,895	Jun 05 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	May 31 '24	Option Exercise	59.21	24,687	1,461,646	70,968	Jun 04 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	May 31 '24	Sale	105.91	34,108	3,612,480	36,860	Jun 04 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Jun 03 '24	Sale	106.43	4,922	523,848	31,938	Jun 04 04:00 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 15 '24	Option Exercise	37.69	5,856	220,736	20,769	May 17 04:05 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 15 '24	Sale	106.96	5,856	626,379	14,913	May 17 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 15 '24	Sale	106.95	3,850	411,772	71,617	May 17 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 08 '24	Option Exercise	2.32	28,181	65,297	75,467	May 10 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 02 '24	Option Exercise	36.05	10,000	360,500	57,286	May 06 05:26 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 02 '24	Sale	105.00	10,000	1,050,000	47,286	May 06 05:26 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Option Exercise	54.13	1,834	99,274	16,747	May 06 05:19 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	103.88	1,834	190,516	14,913	May 06 05:19 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Option Exercise	36.05	5,000	180,250	52,286	Apr 01 04:34 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	95.00	5,000	475,000	47,286	Apr 01 04:34 PM
Albers Jeffrey W.	Director	Mar 07 '24	Sale	90.69	11,033	1,000,583	165,017	Mar 26 09:11 PM
Albers Jeffrey W.	Director	Mar 20 '24	Option Exercise	7.11	25,073	178,287	201,123	Mar 22 05:50 PM
Albers Jeffrey W.	Director	Mar 20 '24	Sale	87.28	25,073	2,188,264	176,050	Mar 22 05:50 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Option Exercise	36.05	5,000	180,250	61,020	Mar 19 05:11 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Sale	87.78	13,734	1,205,606	47,286	Mar 19 05:11 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Option Exercise	15.01	1,600	24,016	18,662	Mar 19 04:48 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Sale	87.76	4,549	399,213	14,913	Mar 19 04:48 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Option Exercise	13.15	1,747	22,975	42,752	Mar 15 04:47 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Sale	90.40	8,023	725,277	34,729	Mar 15 04:47 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Mar 07 '24	Sale	90.69	3,097	280,867	46,281	Mar 11 06:29 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Mar 07 '24	Sale	90.69	5,093	461,884	57,585	Mar 11 06:28 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Mar 07 '24	Sale	90.69	12,464	1,130,360	153,177	Mar 11 06:27 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 07 '24	Sale	90.69	2,934	266,084	41,005	Mar 11 06:26 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 07 '24	Sale	90.69	2,521	228,629	33,853	Mar 11 06:24 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 07 '24	Sale	90.69	5,003	453,722	56,020	Mar 11 06:23 PM
Rossi Christina	CHIEF OPERATING OFFICER	Mar 07 '24	Sale	90.69	6,070	550,488	64,306	Mar 11 06:21 PM
Namouni Fouad	PRESIDENT, R & D	Mar 07 '24	Sale	90.69	4,377	396,950	72,703	Mar 11 06:20 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Mar 07 '24	Sale	90.69	2,286	207,317	48,331	Mar 11 06:19 PM
McCain Tracey L	EVP AND CHIEF LEGAL OFFICER	Mar 07 '24	Sale	90.69	5,194	471,044	60,498	Mar 11 06:18 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 07 '24	Sale	90.69	1,462	132,589	17,862	Mar 11 06:15 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 04 '24	Sale	93.65	621	58,157	36,374	Mar 06 10:41 AM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Option Exercise	54.13	5,000	270,650	29,495	Mar 01 03:06 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Sale	100.00	5,000	500,000	24,495	Mar 01 03:06 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Dec 13 '23	Option Exercise	1.87	261	488	31,439	Feb 14 06:54 PM
Albers Jeffrey W.	Director	Jan 25 '24	Option Exercise	7.13	25,000	178,150	201,050	Jan 29 06:13 PM
Albers Jeffrey W.	Director	Jan 25 '24	Sale	81.91	25,000	2,047,800	176,050	Jan 29 06:13 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 22 '23	Option Exercise	8.80	714	6,283	15,038	Dec 26 04:24 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 22 '23	Sale	90.00	714	64,260	14,324	Dec 26 04:24 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 15 '23	Option Exercise	1.87	3,654	6,833	16,411	Dec 19 04:05 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 15 '23	Sale	84.35	3,914	330,146	14,324	Dec 19 04:05 PM
Albers Jeffrey W.	Director	Dec 11 '23	Option Exercise	36.05	5,000	180,250	181,050	Dec 13 03:56 PM
Albers Jeffrey W.	Director	Dec 11 '23	Sale	79.07	5,000	395,350	176,050	Dec 13 03:56 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 07 '23	Option Exercise	54.13	5,000	270,650	29,495	Dec 11 05:11 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 07 '23	Sale	75.00	5,000	375,000	24,495	Dec 11 05:11 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 04 '23	Sale	71.43	600	42,858	24,495	Dec 06 08:45 PM
Albers Jeffrey W.	Director	Nov 30 '23	Option Exercise	36.05	5,000	180,250	181,050	Dec 04 04:02 PM
Albers Jeffrey W.	Director	Nov 30 '23	Sale	70.55	5,000	352,750	176,050	Dec 04 04:02 PM
Albers Jeffrey W.	Director	Nov 24 '23	Option Exercise	1.87	15,000	28,050	191,050	Nov 28 04:05 PM
Albers Jeffrey W.	Director	Nov 24 '23	Sale	67.51	15,000	1,012,690	176,050	Nov 28 04:05 PM

Open in Screener

SYRE

Spyre Therapeutics Inc

Nov 21 • 04:00PM ET

27.00

Dollar change -0.50
Percentage change -1.82	%

Healthcare • Biotechnology • USA • NASD

SYRE Spyre Therapeutics Inc daily Stock Chart

Peers: AMGN GILD REGN VRTX BIIB MRNA BMY PFE LLY NVS

| Held by: VTI IWM XBI VXF IWN SCHA VTWO DWAS VHT LABU

Index	RUT	P/E	2.93	EPS (ttm)	9.21	Insider Own	17.07%	Shs Outstand	51.43M	Perf Week	-13.66%
Market Cap	1.59B	Forward P/E	-	EPS next Y	-4.23	Insider Trans	-0.25%	Shs Float	42.65M	Perf Month	-19.67%
Income	73.86M	PEG	-	EPS next Q	-1.05	Inst Own	93.56%	Short Float	19.34%	Perf Quarter	5.76%
Sales	0.00M	P/S	-	EPS this Y	90.97%	Inst Trans	110.13%	Short Ratio	15.02	Perf Half Y	-17.38%
Book/sh	3.34	P/B	8.09	EPS next Y	4.57%	ROA	-54.13%	Short Interest	8.25M	Perf Year	170.81%
Cash/sh	7.06	P/C	3.83	EPS next 5Y	-	ROE	-414.82%	52W Range	8.75 - 47.97	Perf YTD	25.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.71%	ROI	22.56%	52W High	-43.71%	Beta	2.86
Dividend TTM	-	Quick Ratio	7.32	Sales past 5Y	-49.91%	Gross Margin	39.53%	52W Low	208.57%	ATR (14)	2.40
Dividend Ex-Date	-	Current Ratio	7.32	EPS Y/Y TTM	111.78%	Oper. Margin	0.00%	RSI (14)	33.99	Volatility	7.46% 7.39%
Employees	30	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.10	Target Price	58.62
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	88.70%	Payout	-	Rel Volume	1.49	Prev Close	27.50
Sales Surprise	-	EPS Surprise	-64.99%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	549.17K	Price	27.00
SMA20	-19.18%	SMA50	-13.61%	SMA200	-13.68%	Trades		Volume	820,948	Change	-1.82%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
04:44PM	Loading…
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
05:23PM	Loading…
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
05:30PM	Loading…
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)
Dec-07-23 06:20PM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire)
Nov-28-23 08:00AM	Spyre Therapeutics to Present at Upcoming Investor Conference (PR Newswire) +20.73%
Nov-27-23 08:30AM	Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD (PR Newswire) +8.79%
Nov-22-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) +6.26%
Nov-09-23 06:26PM	Aeglea: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) -5.39%
Oct-30-23 08:00PM	Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences (PR Newswire) +9.57%
Oct-02-23 06:02PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire)
Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)
Sep-05-23 07:00AM	Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones (PR Newswire)
Aug-11-23 07:07AM	Aeglea: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-27-23 07:00AM	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma (PR Newswire)
Jun-23-23 04:30PM	Aeglea BioTherapeutics Announces Grant of Inducement Awards (PR Newswire) -12.30% -5.30%
10:31AM	Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics (Zacks)
Jun-22-23 10:59AM	Aeglea BioTherapeutics Stock Surges Over 400% Today - What's Going On (Benzinga) +328.67%
08:17AM	Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics (PR Newswire)
May-13-23 08:03AM	Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:15AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Aeglea: Q1 Earnings Snapshot (AP Finance)
07:01AM	Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 09:44AM	Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails (Zacks) -7.37%
Apr-12-23 07:00AM	Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives (PR Newswire) -26.21%
Mar-17-23 05:30PM	Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.35%
Mar-02-23 10:15AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates (PR Newswire)
Feb-12-23 07:40AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 months (Simply Wall St.)
Jan-06-23 07:01AM	Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency (PR Newswire)
Jan-02-23 07:29AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Dec-14-22 12:00PM	Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-02-22 04:05PM	Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +18.17% -5.90%
Nov-30-22 10:38AM	Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease (Benzinga) -65.98%
07:01AM	Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer (PR Newswire)
Nov-15-22 04:25PM	Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer (PR Newswire) -5.88%
Nov-03-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.56%
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +6.02%
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-19-22 04:05PM	Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment (PR Newswire)
Oct-17-22 11:57AM	NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce (Zacks)
Oct-04-22 11:05AM	FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients (Benzinga)
07:01AM	Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program (PR Newswire)
Aug-29-22 04:05PM	Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 (PR Newswire) +16.74% -13.51%
Aug-27-22 09:18AM	Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares (Simply Wall St.)
Aug-25-22 11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-24-22 12:40PM	Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus (Benzinga) -19.87%
08:01AM	Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring (PR Newswire)
Aug-22-22 12:28PM	Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment (Zacks) -17.15%
Aug-20-22 10:49AM	Even after rising 85% this past week, Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders are still down 88% over the past three years (Simply Wall St.)
Aug-19-22 06:26AM	Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today? (Benzinga) +80.23%
Aug-18-22 04:05PM	Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Aug-04-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.41%
07:01AM	Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Jul-24-22 10:41AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks) -5.22%
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.86%
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks)
Jun-09-22 09:56AM	Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is not what insiders may have expected (Simply Wall St.)
Jun-03-22 10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks) -14.51%
Jun-02-22 03:26PM	Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug (Zacks) -51.33%
03:20PM	Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals (Zacks)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Albers Jeffrey W.	Director	Nov 06 '24	Sale	36.76	6,700	246,313	27,360	Nov 08 04:53 PM
Albers Jeffrey W.	Director	Oct 25 '24	Sale	36.43	300	10,929	34,060	Oct 28 04:41 PM
SESSIONS, LLC	Director	Oct 25 '24	Proposed Sale	33.70	7,000	235,900		Oct 25 04:28 PM
Burrows Scott L	Chief Financial Officer	Sep 03 '24	Sale	28.17	18,531	522,074	116,422	Sep 05 04:04 PM
Fairmount Funds Management LLC	Director	Apr 25 '24	Option Exercise	0.00	3,639,680	0	4,018,101	Apr 25 04:55 PM

Open in Screener

KYMR

Kymera Therapeutics Inc

Nov 21 • 04:00PM ET

43.51

Dollar change -0.54
Percentage change -1.23	%

Healthcare • Biotechnology • USA • NASD

KYMR Kymera Therapeutics Inc daily Stock Chart

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI VB IWM VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.33	Insider Own	15.30%	Shs Outstand	55.59M	Perf Week	-5.30%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-2.83	Insider Trans	-5.26%	Shs Float	54.85M	Perf Month	-10.77%
Income	-167.47M	PEG	-	EPS next Q	-0.77	Inst Own	93.73%	Short Float	16.70%	Perf Quarter	-8.94%
Sales	87.56M	P/S	32.18	EPS this Y	-0.13%	Inst Trans	1.64%	Short Ratio	22.23	Perf Half Y	27.07%
Book/sh	13.79	P/B	3.16	EPS next Y	-12.15%	ROA	-21.10%	Short Interest	9.16M	Perf Year	129.48%
Cash/sh	8.49	P/C	5.12	EPS next 5Y	1.90%	ROE	-26.00%	52W Range	18.89 - 53.27	Perf YTD	70.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.18%	ROI	-17.30%	52W High	-18.32%	Beta	2.19
Dividend TTM	-	Quick Ratio	8.55	Sales past 5Y	241.22%	Gross Margin	92.85%	52W Low	130.33%	ATR (14)	2.43
Dividend Ex-Date	-	Current Ratio	8.55	EPS Y/Y TTM	19.04%	Oper. Margin	-223.00%	RSI (14)	40.68	Volatility	5.38% 5.12%
Employees	187	Debt/Eq	0.10	Sales Y/Y TTM	86.92%	Profit Margin	-191.26%	Recom	1.44	Target Price	57.76
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	9.29%	Payout	-	Rel Volume	1.24	Prev Close	44.05
Sales Surprise	-63.81%	EPS Surprise	1.48%	Sales Q/Q	-20.88%	Earnings	Oct 31 BMO	Avg Volume	412.12K	Price	43.51
SMA20	-7.63%	SMA50	-7.38%	SMA200	6.39%	Trades		Volume	510,847	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63
Mar-10-22	Initiated	JP Morgan	Neutral	$44
Feb-10-22	Initiated	Wells Fargo	Overweight	$62
Sep-30-21	Initiated	Stifel	Buy	$80
Sep-30-21	Initiated	B. Riley Securities	Neutral	$67

Show Previous Ratings

Nov-05-24 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-24 03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 08:40AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
09:10AM	Loading…
Oct-30-24 09:10AM	Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-24-24 10:01AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases (GlobeNewswire)
Oct-23-24 07:15AM	Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium (GlobeNewswire)
Oct-09-24 07:00AM	Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Sep-25-24 07:00AM	Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? (Zacks)
Aug-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-21-24 11:15AM	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
01:02PM	Loading…
Aug-20-24 01:02PM	Kymera (KYMR) to Raise $225 Million Through Offering of Shares (Zacks)
07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 10:45PM	Kymera Therapeutics Announces Pricing of $225 Million Public Offering (GlobeNewswire)
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Aug-08-24 09:55AM	Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-07-24 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 (GlobeNewswire) +7.17%
Jul-10-24 08:10AM	Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains? (Zacks) -8.09%
Jul-09-24 01:30PM	Why Kymera Therapeutics Stock Is Soaring Today (Motley Fool) +23.40%
12:22PM	Kymera Therapeutics soars as Sanofi expands phase 2 trials (Investing.com)
10:44AM	Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug (Investopedia)
09:59AM	Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies (Zacks)
07:00AM	Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day (GlobeNewswire)
Jul-08-24 04:05PM	Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy (GlobeNewswire) +5.65%
08:45AM	Loading…
Jun-20-24 08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
Jun-14-24 07:00AM	Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire)
Jun-01-24 08:00AM	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-29-24 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-23-24 05:00PM	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-22-24 11:20AM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) -8.52%
May-08-24 07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-03-24 12:23PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:57AM	Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know (Zacks)
08:44AM	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 (MT Newswires)
03:19AM	Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:18PM	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
11:57AM	KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:00AM	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-19-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-18-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-16-23 07:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma (GlobeNewswire)
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-03-23 04:48PM	Why Shares of Kymera Therapeutics Jumped on Tuesday (Motley Fool) +14.30%
Sep-18-23 07:00AM	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire)
Aug-28-23 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-03-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.07%
07:00AM	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-27-23 07:00AM	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-09-23 09:09AM	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-22-23 08:30AM	Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Esposito Pamela	Director	Sep 17 '24	Option Exercise	23.86	13,500	322,075	13,500	Sep 17 06:20 PM
Esposito Pamela	Director	Sep 17 '24	Sale	48.28	13,500	651,766	0	Sep 17 06:20 PM
PAMELA ESPOSITO	Director	Sep 17 '24	Proposed Sale	48.48	13,500	654,480		Sep 17 04:40 PM
Albers Jeffrey W.	Director	Aug 26 '24	Option Exercise	10.34	5,000	51,700	5,000	Aug 26 06:31 PM
Albers Jeffrey W.	Director	Aug 26 '24	Sale	49.10	5,000	245,508	0	Aug 26 06:31 PM
JOANNA HOROBIN	Director	Aug 26 '24	Proposed Sale	49.16	12,000	589,896		Aug 26 04:32 PM
JEFFREY ALBERS	Director	Aug 26 '24	Proposed Sale	47.78	5,000	238,900		Aug 26 04:25 PM
BAKER BROS. ADVISORS LP	Director	Aug 20 '24	Buy	46.41	1	46	5,516,986	Aug 22 04:03 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Option Exercise	2.08	23,145	48,142	118,885	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Option Exercise	2.08	16,455	34,226	112,195	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Sale	45.81	23,145	1,060,218	95,470	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Sale	45.15	16,455	742,925	95,740	Jul 16 06:00 PM
Booth Bruce	Director	Jul 09 '24	Sale	38.21	453,960	17,346,919	723,246	Jul 09 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '24	Option Exercise	5.33	18,773	100,060	649,959	Jul 01 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 27 '24	Option Exercise	2.08	25,000	52,000	168,554	Jun 28 08:30 AM
Mainolfi Nello	Chief Executive Officer	Jun 18 '24	Option Exercise	2.08	14,413	29,979	631,186	Jun 20 08:30 AM
Booth Bruce	Director	Jun 12 '24	Sale	35.45	16,740	593,378	803,792	Jun 14 06:01 PM
Booth Bruce	Director	Jun 13 '24	Sale	34.98	10,200	356,796	802,022	Jun 14 06:01 PM
Horobin Joanna	Director	Jun 07 '24	Option Exercise	2.08	8,500	17,680	8,500	Jun 07 06:36 PM
Horobin Joanna	Director	Jun 07 '24	Sale	32.99	8,500	280,400	0	Jun 07 06:36 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '24	Sale	34.99	2,575	90,105	44,183	May 23 04:10 PM
Booth Bruce	Director	Mar 15 '24	Sale	40.46	71,764	2,903,336	806,697	Mar 15 07:23 PM
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151	Mar 15 07:23 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266	Mar 13 07:53 PM
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995	Mar 13 07:52 PM
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830	Mar 13 07:52 PM
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266	Mar 13 07:52 PM
Gollob Jared	Chief Medical Officer	Mar 04 '24	Sale	41.86	3,344	139,967	95,740	Mar 04 06:21 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '24	Sale	41.86	3,934	164,664	142,351	Mar 04 06:12 PM
Albers Jeffrey W.	Director	Feb 21 '24	Option Exercise	10.34	4,385	45,341	4,385	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Option Exercise	10.34	615	6,359	615	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 21 '24	Sale	39.05	4,385	171,227	0	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Sale	39.07	615	24,031	0	Feb 21 06:46 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Option Exercise	2.08	46,137	95,965	120,846	Feb 09 07:47 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Sale	35.50	46,137	1,638,071	74,709	Feb 09 07:47 PM
Albers Jeffrey W.	Director	Jan 23 '24	Option Exercise	10.34	10,000	103,400	10,000	Jan 23 07:37 PM
Albers Jeffrey W.	Director	Jan 23 '24	Sale	30.05	10,000	300,470	0	Jan 23 07:37 PM
Chiniara Ellen	Chief Legal Officer	Jan 04 '24	Sale	22.58	3,295	74,416	34,205	Jan 05 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jan 02 '24	Option Exercise	2.08	9,000	18,720	615,570	Jan 02 05:43 PM

BPMC

Blueprint Medicines Corp

SYRE

Spyre Therapeutics Inc

KYMR

Kymera Therapeutics Inc

Upgrade your FINVIZ experience